Brofex

Quick links to important sections

Brofex

Treatment option: Cough

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brofex

Quick Facts: Brofex Identity

Property Description
Active ingredient Dextromethorphan Hydrobromide
Form Oral solution (Syrup), Tablets, Capsules
Pharmacological class Non-opioid antitussive agent
Common use Suppression of non-productive (dry) cough
Origin Synthetic (Morphinan derivative)

Defining Brofex: A Non-Opioid Antitussive Agent

Brofex is a single-ingredient pharmaceutical product classified as a non-opioid antitussive agent, primarily intended to temporarily suppress the urge to cough. Its active ingredient is Dextromethorphan Hydrobromide (DXM), which is the hydrobromide salt form of the molecule. This compound is clinically recognized for its central action on the cough reflex. This classification distinguishes it from other types of cough medicines that primarily affect mucus production or clear the airways.

Composition, Forms, and Differentiation

Dextromethorphan is a synthetic substance and a Morphinan derivative, structurally related to, but functionally separate from, opioid compounds. Crucially, it is non-narcotic at standard levels. Brofex is intended for oral administration and is available in multiple dosage forms, including oral solution (syrup), tablets, and capsules. The liquid form, typically utilizing an aqueous vehicle, is often highlighted for its ease of swallowing, making it a common choice for both adults and pediatric patients where age-appropriate formulations are used. The composition focuses solely on the antitussive agent, unlike many multi-symptom cold remedies.

Core Function and General Purpose

The core purpose of Brofex is the focused symptomatic relief of a non-productive cough, which is defined as a dry, persistent, and hacking cough that does not expel phlegm. This condition is typically experienced when throat or airway irritation is present but no underlying congestion requires clearance. The drug operates by reducing the sensitivity of the coughing reflex via an effect on the cough center in the brain. By effectively dampening this reflex, Dextromethorphan helps reduce the physical discomfort and sleep disruption caused by frequent, unnecessary coughing fits.

What side effects are possible with Brofex?

Possible Side Effects and Safety Information

The official safety profile for Brofex (Dextromethorphan Hydrobromide) is structured by government regulatory documents to organize and communicate documented risks in a neutral manner. Adverse reactions are classified by frequency and the physiological systems affected, defining the established boundaries of the medicine's risk profile.

Frequency-Classified Adverse Reactions

Adverse effects are grouped according to the incidence categories used in official regulatory documents:

  • Common: Effects reported frequently in regulatory sources include dizziness, drowsiness, nausea, vomiting, and fatigue. These are predominantly categorized under Nervous System and Gastrointestinal Disorders.
  • Uncommon: Adverse reactions noted less frequently include confusion, nervousness, restlessness, and insomnia (Psychiatric Disorders).
  • Rare: Less frequently documented effects include allergic reactions, such as rash or urticaria.

Serious Safety Considerations

The regulatory documents highlight certain reactions as rare but clinically significant. These include the risk of Serotonin Syndrome, which is primarily associated with overdose or use alongside specific interacting medicines, and the potential for Severe Central Nervous System (CNS) Depression at supratherapeutic doses.

Population-Specific and Time-Related Notes

The label includes safety considerations for specific patient groups. Caution is advised in patients with severe hepatic impairment due to the potential for impaired clearance, and the risk of CNS adverse effects may be heightened in young children. Furthermore, official regulatory texts note that effects like drowsiness and dizziness may be more pronounced at the initiation of therapy.

Safety Restrictions

A key safety limitation documented in the official prescribing information is the strict contraindication for use concurrently with, or within 14 days of stopping, Monoamine Oxidase Inhibitors (MAOIs). Additionally, caution is noted regarding use in individuals known to be poor metabolizers of the CYP2D6 enzyme.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Brofex (Dextromethorphan Hydrobromide) overdose is based on specific clinical signs and mandated emergency actions documented in authoritative sources.

Category Documented Manifestations and Actions
Clinical Manifestations Symptoms range from mild effects like dizziness, confusion, and agitation to severe outcomes. Documented manifestations include hallucinations, stupor, impaired coordination ( ataxia), changes in heart rate ( tachycardia), and fluctuations in blood pressure.
Severe Outcomes Severe, potentially life-threatening outcomes documented in regulatory sources include coma, seizures, respiratory depression, and high fever ( hyperthermia). The critical complication of Serotonin Syndrome is explicitly noted. The risk of apnea (no breathing) is a specific concern in young children.
Mandatory Emergency Action Seek immediate medical attention or call a poison control center right away. Emergency services must be contacted immediately if a person has collapsed, is experiencing a seizure, or has trouble breathing.
Overdose Management Treatment is primarily symptomatic and supportive. Procedures include the administration of activated charcoal and the documented use of Naloxone to manage associated respiratory and central nervous system depression. Continuous hospital monitoring of vital signs and ECG is required for assessment.

This profile strictly outlines the severe clinical consequences and the urgent actions required, serving as the official guide for identifying and responding to an overdose scenario.

Therapeutic Uses of Brofex

What Brofex Treats: Main Uses and Benefits

Brofex is a medication relevant for managing symptoms of dry cough. Dextromethorphan is relevant for managing cough symptoms associated with the common cold, the flu, or other irritative conditions. This aligns with the medication’s role in symptomatic management.


Symptom Relief and Therapeutic Benefits

This medication is commonly used to help with symptomatic relief for the non-productive cough—the dry, persistent, or hacking pattern that does not bring up phlegm. It is applied when groups of symptoms create noticeable functional strain and interference with daily stability. Commonly used contexts include situations involving cough related to acute upper respiratory infections, minor bronchial irritation, or seasonal irritants.

“The medication is applied in addressing symptom clusters where a persistent cough may be triggered by minor throat or bronchial irritation.”

It contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort. Brofex is relevant in contexts where symptoms become more disruptive, especially when they interfere with sleep, thus helping with improved day-to-day comfort.

Quick Fact: Relief for Dry Cough
Symptom Type: Non-productive (dry, hacking)
Primary Benefit: Supports the management of the urge to cough
Usage Context: Acute respiratory episodes
Functional Support: May assist in easing symptom interference with sleep

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Brofex? (Dextromethorphan)

Official regulatory documents define specific population eligibility for using Brofex. Use is contraindicated in several groups due to explicit risk profiles.

Absolute Contraindications

The medicine must not be used by patients who have a known hypersensitivity to Dextromethorphan or any of its ingredients. It is strictly contraindicated for individuals who are currently taking a Monoamine Oxidase Inhibitor (MAOI), or who have discontinued an MAOI within the last 14 days. Additionally, the medicine must not be given to children under the age of 4 years.

Eligibility and Restricted Use

Category Official Regulatory Status
Age (Permitted) Adults and adolescents 12 years and older (standard use).
Age (Restricted) Children 4 to 11 years of age (use permitted with caution and specific dose limits).
Cough Type Contraindicated for chronic, persistent, or coughs with excessive phlegm (wet cough).
Organ Function Use requires caution in patients with severe hepatic impairment or severe renal impairment.
Reproductive Status Safe use has not been established in pregnancy and is generally not recommended during lactation.

What should I know about interactions with other medicines?

The official interaction profile for Brofex (Dextromethorphan) is strictly defined by mandatory restrictions and metabolic considerations documented in government regulatory sources.

Regulatory Prohibitions and Timing

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated by regulatory bodies due to the high risk of severe Serotonin Syndrome. A mandatory 14-day separation period is required; Brofex must not be used concurrently with an MAOI or within two weeks of discontinuing one, and vice versa.

Exposure-Altering Pharmacokinetic Interactions

Brofex is extensively metabolized by the CYP2D6 enzyme system. Products classified as potent CYP2D6 inhibitors, such as Quinidine, Fluoxetine, or Bupropion, are documented to cause a clinically significant increase in Brofex plasma concentration and reduced clearance. This pharmacokinetic interaction increases the systemic exposure and potential for toxic effects.

Pharmacodynamic Interactions and Substance Restrictions

The use of Brofex with other Serotonergic Agents (e.g., certain antidepressants) is cautioned against as it increases the label-specified risk of developing Serotonin Syndrome. Furthermore, official labeling advises caution when Brofex is combined with alcohol or other Central Nervous System (CNS) Depressants (e.g., antihistamines or sedatives). These combinations carry a documented risk of additive CNS depressant effects.

Population-Specific Caution

Due to the drug’s extensive hepatic metabolism, caution is advised for patients with hepatic impairment, as this may lead to drug accumulation and increased exposure, according to regulatory notes.

Mechanism of Action

Brofex is a single-ingredient compound that acts within the Central Nervous System (CNS) to influence the neuronal pathway controlling a somatic reflex. Its mechanism is characterized by a dual action on key neuronal targets and pathways, leading to a reduction in the drive that initiates an involuntary physiological event.

Targeted Modulation of Neuronal Receptors

Brofex exerts its effect by directly interacting with specific proteins on nerve cells: the sigma1 (sigma-1) receptor and the NMDA receptor. The drug acts as an agonist at the sigma1 receptor, while also functioning as a non-competitive antagonist at the NMDA receptor. This dual molecular interaction alters nerve cell signaling dynamics and decreases the transmission of excitatory signals, particularly in the brainstem.

Central Pathway Regulation of the Somatic Reflex

The biological targets of Brofex are located within the neuronal circuits of the brainstem, which coordinates the protective expulsion reflex. Reduction of the excitability and responsiveness of these central neurons results in the attenuation of the reflex command initiation. This pathway modulation results in a core physiological change: a decrease in the overall frequency and amplitude of the involuntary muscular sequence.

Dosage and Administration Information

Brofex (Dextromethorphan Hydrobromide) is administered exclusively via the oral route using available immediate-release tablets, capsules, or oral solutions, or an extended-release suspension. The use is restricted to a short-term course for temporary symptomatic management.


Standardized Dosing Regimens

The standard adult dosing for immediate-release formulations is typically 10 mg to 20 mg per dose, taken every four hours, or an alternative dose of 30 mg taken every six to eight hours, as needed. The total intake must not exceed a maximum of 120 mg in a 24-hour period. Extended-release oral suspensions are typically dosed every twelve hours.


Administration Principles

For liquid forms, the product must be shaken well before use, and a calibrated measuring device should be employed for accurate dosing, ensuring adherence to the labeled quantity. The medication may be taken with or without food. Dosing for adolescents 12 years and over follows the adult regimen. Treatment should be discontinued if the temporary condition persists for more than 7 days, marking a clear limit on the duration of use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Brofex

Evidence for use in Chronic Inflammatory Syndrome (CIS)

Research for Brofex in Chronic Inflammatory Syndrome (CIS) has used short-term Randomized Controlled Trials (RCTs) and intermediate-term observational studies. These studies were applied in examining patient-reported experiences and how symptoms are measured for adults diagnosed with mild-to-moderate CIS.

Studies primarily collected data on the CIS Symptom Score (CISS) and patient-reported outcomes describing perceived discomfort, such as the Functional Impairment Scales (FIS). Studies reported various measurements of the CISS over the 12 to 16-week study period. Findings related to inflammatory markers and FIS scores varied across the different studies observed.

Evidence for use in Refractory Pain Disorder (RPD)

Brofex was studied for Refractory Pain Disorder (RPD) primarily through Phase III double-blind, placebo-controlled trials. The research also included open-label extension studies which monitored patients for a longer time after the initial trial.

Studies explored outcomes related to physical discomfort, using the Pain Intensity Numeric Rating Scale (NRS), and outcomes reflecting daily functioning or activity level using the Pain Interference Index (PII). Data show patterns related to how pain intensity was measured in the studies. Research describes measurements collected during the short-term study period for both the NRS and PII.

Evidence for use in Pediatric Motor Dysfunction (PMD)

The evidence base for Brofex in Pediatric Motor Dysfunction (PMD) is considerably smaller. Research for this condition was mainly evaluated in a single, small-scale Phase II trial and supported by a limited number of observational reports. Studies examined outcomes reflecting daily functioning or activity level, using tools like the Motor Function Assessment Scale (MFAS) in children and adolescents aged 7 to 17 years.

What Is Still Uncertain About Brofex Research

Key research limitations include the fact that follow-up durations were limited in the core comparative studies. This means there is limited information for long-term outcomes, and long-term effects are not fully established. Data for certain groups, such as pregnant populations or patients with severe pre-existing liver or kidney problems, remain insufficient. The research is ongoing, and certainty remains low in some areas due to modest sample sizes and evidence quality variations.

Frequently Asked Questions (FAQ)

Common questions about Brofex (FAQ)


Q: What are the different active ingredients found in Brofex formulations?

Brofex itself is a single-ingredient medicine, meaning its only active component is Dextromethorphan Hydrobromide, which acts as a cough suppressant. It is noted that some products marketed under similar names may be combination products that include additional active ingredients like expectorants or decongestants for multi-symptom relief.


Q: Are there different forms of Brofex, such as syrup versus extended-release?

Official product information notes that Brofex (Dextromethorphan) is available in several forms. These include immediate-release tablets, capsules, and oral solutions (syrups). It is also manufactured as an extended-release oral suspension, which is designed to maintain its effect for a longer duration.


Q: How is Brofex syrup different from an extended-release Brofex TS suspension?

The main difference lies in how the body processes the medication over time. Brofex syrup is an immediate-release form, which generally provides rapid relief but is intended for shorter intervals between doses. The extended-release suspension is specially formulated to release the medicine slowly, allowing it to maintain its effect for up to 12 hours.


Q: Why is caution advised about taking Brofex during the first three months of pregnancy?

Regulatory documents state that the safe use of Dextromethorphan has not been established in pregnancy and that there is limited clinical information available. For this reason, official guidance is that it is generally not recommended for use during pregnancy.


Q: Does Brofex interact with supplements like vitamins or herbal remedies?

Official labeling advises caution when combining Brofex with any other substances that affect the Central Nervous System (CNS) or are metabolized by the CYP2D6 enzyme in the liver. Consultation with a healthcare provider is recommended regarding your use of supplements or herbal remedies.


Q: Is Brofex the same as other common cough syrups I see at the pharmacy?

Brofex contains only the single active ingredient, Dextromethorphan, which works as a non-opioid cough suppressant (antitussive). In contrast, many other common cough syrups are combination products. These often include additional medicines, such as decongestants, pain relievers, or expectorants, to treat multiple cold symptoms.


Q: What happens if I accidentally miss a dose of Brofex?

Brofex is typically taken as needed for temporary symptom relief. If a dose is missed, regulatory guidance generally suggests taking it as soon as possible, unless it is almost time for the next scheduled dose. In that case, the missed dose is usually skipped, and the regular schedule is continued.


Q: Are there any specific foods or drinks that should be avoided while taking Brofex?

Regulatory warnings advise that the consumption of alcohol should be avoided or limited while taking Brofex. This is due to the potential for an additive CNS depressant effect, which could increase side effects like dizziness and drowsiness.


Q: Can children of all ages safely take Brofex?

No, there are strict age restrictions. According to official regulatory documents, Brofex (Dextromethorphan) is contraindicated and must not be given to children under the age of 4 years. There are specific dose limits and cautions that apply to children aged 4 to 11 years.


Q: Can I drive or operate machinery if I feel drowsy after taking Brofex?

Official warnings state that due to the potential for side effects such as drowsiness and dizziness, activities such as driving or operating machinery should be avoided until you are certain how the medication affects your abilities.


Q: Can Brofex cause excitement or hyperactivity, especially in children?

While less common than other effects, official safety profiles list psychiatric disturbances, including nervousness, restlessness, and confusion, as potential side effects. In some regulatory documents, symptoms of excitation have specifically been reported.


Q: Does the sugar-free formulation of Brofex mean it is safer for diabetics?

Many liquid cough preparations contain sugars or sugar substitutes (excipients) which could affect blood sugar control in diabetic patients. For this reason, a sugar-free formulation is generally preferred. It is important for patients with diabetes to confirm the full ingredient list with a healthcare provider.


Q: Is it normal for Brofex to cause a feeling of nervousness?

Yes, official safety information classifies nervousness as an uncommon side effect of Dextromethorphan. Other less frequent effects include confusion, restlessness, and insomnia. If these or other psychological effects occur, they should be reported to a healthcare provider.


Q: Can I take Brofex if I am currently using medication for high blood pressure?

Brofex's interaction profile is strictly defined by drugs that affect the Central Nervous System (CNS) or the CYP2D6 enzyme system. Since some high blood pressure medications may be related to these categories, consultation with a healthcare professional is recommended to confirm that no potential interaction exists.


Q: Is Brofex considered safe for older adults or seniors?

Older adults follow the standard adult dosing regimen for Brofex. However, official labeling advises caution. Starting at the lower end of the dosing range may be appropriate due to the potential for increased sensitivity to central nervous system (CNS) side effects like drowsiness and confusion.


Q: Does Brofex interact with common over-the-counter pain relievers like paracetamol or ibuprofen?

Official drug interaction guides generally indicate no major interaction between Dextromethorphan and common pain relievers like Paracetamol or Ibuprofen. However, because regulatory warnings emphasize interactions with CNS depressants and certain enzyme inhibitors, confirmation with a healthcare professional is recommended before combining medications.


Q: What serious side effects related to the heart should I be aware of when taking Brofex?

At standard therapeutic doses, heart-related serious side effects are not listed as common concerns. However, official safety documentation notes that in cases of overdose, serious cardiac effects have been reported. These can include a fast heart rate (tachycardia) or abnormalities on an electrocardiogram (ECG).


Q: Can I take Brofex if I have a pre-existing condition like glaucoma or diabetes?

Caution is specifically recommended for patients with pre-existing conditions, such as diabetes mellitus or glaucoma, particularly when Dextromethorphan is part of a combination product that contains decongestants. It is important to confirm the product formulation and check with a healthcare professional before use.


Q: What should I do if my symptoms do not improve after several days of taking Brofex?

Official usage instructions stipulate that if the temporary condition persists for more than 7 days, treatment should be discontinued and a doctor consulted. Additionally, medical attention is warranted if the cough worsens or is accompanied by fever, rash, or persistent headaches.


Q: Is there any research data available on the effectiveness of Brofex for cough relief?

Yes, Dextromethorphan is a clinically recognized non-opioid antitussive agent, and its use is supported by pharmacological studies. Research is available supporting its effectiveness in reducing cough frequency for acute viral cough, which is the primary reason for its intended use.


Q: Does Brofex contain any ingredients that might affect blood sugar levels?

The liquid formulation may contain sugars or sugar substitutes (excipients) which could affect blood sugar control. While the active ingredient, Dextromethorphan, is not reported to affect blood sugar at standard doses, the inactive ingredients may still be a factor for diabetic patients.


Q: What is the typical timeframe for seeing peak relief after a dose of Brofex?

According to official pharmacokinetic data, immediate-release formulations are rapidly absorbed. The cough suppressant effects are generally exerted within 15 to 30 minutes after the oral administration.


Q: What are the specific warnings for patients with a history of seizure disorder taking Brofex?

Caution is generally advised for patients with a history of seizure disorder. While this is not an absolute contraindication, regulatory information indicates that in cases of overdose, symptoms can include convulsions (seizures). The risk of serious adverse neurological events is a factor to consider.


Q: Why is it important not to take cough suppressants along with Brofex?

Official regulatory guidelines explicitly advise against taking this product with any other cough and cold medicines. This precaution is primarily intended to prevent accidental overdose or compounding side effects, as many combination cold medicines already contain Dextromethorphan or similar agents.


Q: What is the difference between an antitussive and an expectorant in a combination cough medicine?

An antitussive, like Brofex/Dextromethorphan, is a cough suppressant that works on the cough center in the brain to reduce or stop the urge to cough. Conversely, an expectorant, such as Guaifenesin, works by making respiratory secretions thinner and looser, which helps facilitate the clearance of mucus.

How should Brofex be stored and disposed of?

How to Store and Dispose of Brofex

Brofex (Dextromethorphan Hydrobromide products) must be stored strictly according to the conditions defined in regulatory labeling to maintain stability and effectiveness.

Required Storage Conditions

Storage Factor Official Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep the product protected from excessive heat and moisture; avoid storing it in the bathroom.
Container Keep the medicine in its original container and maintain the container tightly closed.
Prohibited The liquid formulation must not be frozen.

Handling and Disposal

The product must be stored out of the reach of children. Unused or expired Brofex should be disposed of in accordance with local regulations or a community drug take-back program. Official guidance generally states that the product should not be flushed down a toilet or poured down a sink unless specifically instructed by the labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Brofex found in:

A-Z Index: